-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In non-small cell lung cancer, 15% of tumors are mainly composed of EGFR-sensitive cells, and EGFR inhibitor treatment can kill these cells
Image source: Sordella lab/CSHL
When doctors give a patient antibiotics to treat a bacterial infection, they usually ask the patient to complete the entire treatment, even if the symptoms have disappeared
Approximately 15% of non-small cell lung cancers have a mutation in the growth receptor EGFR, which causes tumor cells to grow uncontrollably
Sordella and her team found that before treatment, a small percentage of drug-resistant cancer cells already existed
Sordella and her team collaborated with Northwell Health Center clinician and former CSHL professor Gregory Hannon, who now works at the Cancer Institute in Cambridge, UK
Sordella explained: “The genome is like a library
Researchers discovered that a microRNA called miR335 determines the "state" of cancer cells
Understanding how drug resistance occurs in lung cancer is the key to finding the elimination of tumors
Safaric Tepes, P.
# # #
